<DOC>
	<DOC>NCT00724841</DOC>
	<brief_summary>Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.</brief_summary>
	<brief_title>A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma</brief_title>
	<detailed_description>GMX1777 will be administered as 3-Hour Infusions in Combination with Temozolomide taken orally for the treatment of Metastatic Melanoma. GMX1777 infusion will be given on either day 1, days 1 and 3, or days 1,3, and 5 every 4 weeks. Temozolomide will be administered on 5 consecutive days every 4 weeks. No investigational or commercial agents or therapies other than those described may be administered with the intent to treat the patient's malignancy.</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically or cytologically confirmed metastatic melanoma Up to 1 prior chemotherapy regimen allowed; prior immunotherapy allowed Normal organ and marrow function Willing to submit to blood sampling for planned PK/PD analyses Ability of understand and willingness to sign a written informed consent No other investigational or commercial agents or therapies Prior exposure to GMX1777, GMX1778 or CHS828 Patients with uncontrolled, intercurrent illness Pregnant or breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>